DIA Product, News Roundup
Almac’s New Clinical Supply Chain Value-AddTheorem Clinical Research Debuts New BrandingHealthcare Businesswomen’s Association and DIA Form Leadership InitiativeVodafone, Exco InTouch Partners in Patient Reported Outcomes and Patient EngagementPhlexglobal Re-Brands Around TMF ExpertisePAREXEL MyTrials Fully Integrated eClinical Workflow SolutionPharmaNet/i3’s New IRT Release for Randomization, SupplyOracle’s New Version for Translational ResearchDrugDev Survey on Study Start-Up, Site IdentificationTrifecta Multimedical, Web-based Investigator TrainingNew Name, Brand for Clinical Financial ServicesOpen SafeGuard Manages Social Platforms for Potential RiskIntraLinks’ Second Year Global Investigator Site SurveyQuanticate Launches Next Generation Functional Service ProvisionBBK Worldwide Launches Online Patient Recruitment Purchasing PowerMerge eClinical OS, Clinical Trial Operating SolutionComprehend Systems, Analytics in the CloudY-Prime’s Content Review Publishing Tool
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
